ITHUF · iANTHUS CAPITAL HOLDINGS, INC.
$0.00
0.00 (-24.00%)
At close · Jul 21
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the substantial losses and working capital deficiency cast substantial doubt on the Company's ability to continue as a going concern for a period of no less than 12 months from the date of this report.”View the 10-Q filed May 12, 2026
Market Cap
$26.50M
Shares
6.97B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$143.99M
-14.1%
FY2025
Net Income
-$40.2M
-426.5%
FY2025
Gross Margin
45.63%
+0.8pp
FY2025
Operating Margin
-10.71%
-5.6pp
FY2025
Diluted EPS
-$0.01
FY2025
Operating Cash Flow
$3.15M
-74.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $139.38M | $143.99M | $167.57M | $159.24M | $163.21M | $203.02M | $151.67M | |
| $76.64M | $78.29M | $92.45M | $96.07M | $88.78M | $93.49M | $69.83M | |
| $62.74M | $65.7M | $75.11M | $63.17M | $74.43M | $109.53M | $81.84M | |
| — | 45.63% | 44.83% | 39.67% | 45.6% | 53.95% | 53.96% | |
| $58.39M | $60.89M | $62.18M | $67.86M | $128.09M | $96.97M | $98.38M | |
| — | $10.2M | $13.9M | $13.9M | $16.4M | $15.4M | $15.5M | |
| — | $19.29M | $24.74M | $27.17M | $31.39M | $31.04M | $27.92M | |
| $78.44M | $81.11M | $83.63M | $92.9M | $186.89M | $133.31M | $331.73M | |
| — | — | — | — | $0 | $1.9M | $0 | |
| -$15.7M | -$15.42M | -$8.51M | -$29.74M | -$112.46M | -$23.78M | -$249.89M | |
| — | -10.71% | -5.08% | -18.67% | -68.9% | -11.71% | -164.76% | |
| — | $3.87M | $16.22M | -$2.57M | -$81.07M | $7.26M | -$221.97M | |
| — | $16.6M | $17.17M | $15.75M | $18.66M | $1.7M | $3.4M | |
| — | — | — | — | $86K | $517K | $403K | |
| — | -$13K | -$211K | -$183K | $0 | $0 | $182K | |
| -$39.64M | -$23.17M | -$25.31M | -$49.46M | -$438.7M | -$55.75M | -$294.73M | |
| $20.02M | $17.04M | -$17.68M | $27.16M | $10.69M | $21.74M | $18.63M | |
| -$59.66M | -$40.2M | -$7.64M | -$76.62M | -$449.39M | -$77.49M | -$313.36M | |
| — | -27.92% | -4.56% | -48.12% | -275.34% | -38.17% | -206.61% | |
| USD/shares | — | -$0.01 | $0.00 | -$0.01 | -$0.13 | -$0.45 | — |
| USD/shares | — | -$0.01 | $0.00 | -$0.01 | -$0.13 | -$0.45 | — |
| shares | — | 6.7B | 6.54B | 6.44B | 3.37M | 171.72K | 171.65M |
| shares | — | 6.7B | 6.54B | 6.44B | 3.37M | 171.72K | 171.65M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.22×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.94×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 19.97×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Eastern Region | $133,605,000 | $128,553,000 | $105,922,000 | $96,478,000 | $128,979,000 | $91,149,000 |
| Western Region | $10,381,000 | $39,014,000 | $53,088,000 | $65,644,000 | $72,424,000 | $57,613,000 |
| Other | — | — | $227,000 | $1,091,000 | $1,615,000 | $2,907,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Ianthus Branded Products | $63,168,000 | $84,904,000 | $87,545,000 | $86,626,000 | $117,617,000 | $83,688,000 |
| Third Party Branded Products | $55,128,000 | $64,506,000 | $61,108,000 | $66,959,000 | $64,267,000 | $48,024,000 |
| Wholesale Bulk Other Products | $25,690,000 | $18,157,000 | $10,584,000 | $9,628,000 | $21,134,000 | $19,957,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Eastern Region | $4,684,000 | $12,463,000 | -$6,971,000 |
| Western Region | -$963,000 | -$927,000 | $1,103,000 |
| Other | -$19,139,000 | -$20,049,000 | -$23,867,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Eastern Region | 3.5% | 9.7% | -6.6% |
| Western Region | -9.3% | -2.4% | 2.1% |
| Other | — | — | -10514.1% |